LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors
The newly formed AAV Development Program will focus on developing next-generation synthetic adeno-associated virus (AAV) capsids capable of overcoming many of the current limitations of existing viral vectors. LogicBio will hold exclusive worldwide commercial rights to vectors developed under the partnership, with the goal of commercializing the new capsids as widely as possible.
"We’re optimistic that we can significantly improve the performance of AAV vectors through this collaboration,” said
The AAV Development Program will be led by Professor
Dr. Lisowski, a scientific co-founder of
Over the past few decades, AAV has emerged as a potent, versatile and safe platform for gene delivery into cells in vitro and in vivo. Current clinical applications of gene therapy and gene editing are largely based on families of AAVs discovered over 10 years ago. There is now a pressing need to identify new and improved vectors with greater tissue tropism, improved immunogenic profile, enhanced manufacturability and optimization for delivering different payloads.
“We are confident that we can further improve on the performance of current AAV vectors, expanding their utility in a range of tissues, while also improving manufacturability and reducing cost,” said Dr. Lisowski.
CMRI and its clinical partner, SCHN, have long contributed to pioneering work in the clinical translation of cell and gene therapies, including being the first in
"With the AAV Development Program, CMRI continues to build upon its groundbreaking work to facilitate the development of novel vectors and therapies, as well as the clinical translation of those efforts. Our goal is to ensure that these life-saving therapies are made available to our patients and the wider community," said Professor Alexander.
LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.
For more information, please visit www.logicbio.com.
CMRI pioneered microsurgery, immunizations against lethal childhood illnesses and care for premature babies, improving the lives of countless Australian children over the last 60 years. Today, CMRI is an independent institute and the site of world-leading research in the areas of cancer, neurobiology, embryology, proteogenomics and gene therapy.
CMRI collaborates with scientists all over the world to move research forward. It also provides important resources for scientists in
CMRI, based in
CMRI’s achievements are made possible by a network of devoted community supporters, as well as the iconic Jeans for Genes® fundraising campaign. www.cmri.org.au
Stern Investor Relations
Ten Bridge Communications
+612 8865 2803
Source: LogicBio Therapeutics